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Stem cell transplantation has been considered a possible therapeutic method for neuropathic pain. However,
no quantitative data synthesis of stem cell therapy for neuropathic pain exists. Therefore, the present sys-
tematic review and meta-analysis assessed the efﬁcacy of bone marrow mesenchymal stem cell (BMMSC)
transplantation on alleviating pain symptoms in animal models of neuropathic pain. In the present meta-
analysis, controlled animal studies assessing the effect of administrating BMMSC on neuropathic pain were
included through an extensive literature search of online databases. After collecting data, effect sizes were
computed and the standardized mean difference (SMD) with 95% conﬁdence interval (CI) was entered in all
analyses. Random-effects models were used for data analysis. Sensitivity and subgroup analyses were per-
formed to investigate expected or measured heterogeneity. Finally, 14 study were included. The analyses
showed that BMMSC transplantation lead to signiﬁcant improvement on allodynia (SMD ¼ 2.06; 95% CI, 1.09
to 3.03; I2 ¼ 99.7%; P < .001). The type of neuropathy (P ¼ .036), time between injury and intervention (P ¼
.02), and the number of transplanted cells (P ¼ .023) inﬂuence the improvement of allodynia after BMMSC
transplantation. BMMSC transplantation has no effect on hyperalgesia (SMD ¼ .3; 95% CI, 1.09 to 1.68; I2 ¼
100%; P < .001) unless it occurs during the ﬁrst 4 days after injury (P ¼ .02). The present systematic review
with meta-analysis suggests that BMMSC transplantation improves allodynia but does not have any signiﬁ-
cant effect on hyperalgesia unless it is given during the ﬁrst 4 days after injury.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Neuropathic pain is deﬁned as chronic pain resulting from
a lesion or disease affecting the somatosensory system [1]. It
can be triggered by central or peripheral nerve injury. The
predominant symptoms are acute or sharp pain, impulsive
pain, hyperalgesia, and allodynia. These symptoms may have
continuous or episodic (paroxysmal) components [2].
Epidemiological evidence shows that the prevalence of
neuropathic pain in general population is 3% to 17% [3].
Neuropathic pain leads to decreased quality of life, reduced
personal functions, and undermined mental health and so-
cial relations. It is 1 of the most complicated pain conditionsdgments on page 1543.
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ty for Blood and Marrow Transplantation.to diagnosis and treat, and outcome is often poor [4,5].
Current treatment strategies only decrease 30% to 40% of the
pain in less than 50% of the patients. Medications are aligned
with some problems, such as side effects. New studies sug-
gest that regenerative approaches based on cell therapy may
be helpful in alleviating neuropathic pain symptoms [6-10].
In the last 2 decades, stem cell transplantation has been
considered a possible therapeutic method for the spinal
cord injury and neuropathic pain conditions [6,9-13].
Mesenchymal stem cells are the main source of cell
therapy because of their ability of differentiating into mul-
tiple cell types, including blood, adipose tissue, connective
tissues, osteocytes, chondrocytes, hepatocytes, myocytes,
neurons, and cardiomyocytes [14-16]. Bone marrow
mesenchymal stem cells (BMMSCs) can easily grow in vitro
and exhibit intriguing immunomodulatory properties,
nonteratogenicity, and multipotentiality with high genetic
stability. They can also improve synaptic transmission and
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M. Hosseini et al. / Biol Blood Marrow Transplant 21 (2015) 1537e15441538promote neuronal networks [17-21]. These properties make
BMMSCs prime candidates for various therapeutic applica-
tions, especially for nervous system repair. In the context of
neuropathic pain, transplantation of BMMSCs into the
injured spinal cord reduced the progress of neuropathic
pain [6,22-24].
Few clinical studies have been published regarding the
use of BMMSCs for spinal cord injury. The ﬁndings of these
studies have substantial diversity, ranging from improve-
ment in symptoms to no signiﬁcant improvement [25-32].
These studies have lacked a proper randomized control
group and have been underpowered. However, a substantial
number of controlled preclinical studies have investigated
the effect of BMMSCs on neuropathic pain [6,22-24,33-41].
These studies revealed various degrees of improvement of
neuropathic pain and symptoms, such as allodynia and
hyperalgesia. Yet there is not a general conclusion about the
effectiveness of stem cells in neuropathic pain. For this pur-
pose, a meta-analysis of controlled studies could help esti-
mate the effect of the intervention and, therefore, yield more
powerful decision making. However, to our knowledge, no
quantitative data synthesis of stem cell therapy for neuro-
pathic pain exists. Therefore, the present systematic review
and meta-analysis assessed the efﬁcacy of BMMSCs trans-
plantation on alleviating pain, allodynia, and hyperalgesia in
animal models of peripheral or central neuropathic pain.Tr
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Search Strategy
The study was conducted according to Meta-analysis of Data from An-
imal Studies Guidelines [42,43], providing a detailed guideline of preferred
reporting for systematic reviews and meta-analyses. Relevant articles were
identiﬁed through a literature search of online databases (PubMed, SCOPUS,
Embase, Cochrane, and CINAHL) without publication date and language
limitations. The initial search was broad and included the following words:
(1) PubMed term: (“mesenchymal stem cells” OR “mesenchymal stromal
cells” OR “mesenchymal stem cell” OR “mesenchymal stromal cell” OR
“marrow stromal cell” OR “bone marrow stem cell” OR “bone marrow-
derived stromal cell” OR “mesenchymal precursor cell” OR “MSCs” OR
“MSC” OR “BMSCs” OR “BMSC”) AND (“spinal cord injuries” OR “spinal”
“spinal cord injury” OR “spinal cord contusion” OR “spinal cord transection”
OR “injured spinal cord” OR “pain” OR “pain” OR “neuropathic pain” OR
“allodynia” OR “hyperalgesia” OR “hypersensitivity”); and (2) In EMBASE:
(mesenchymal stem cells.mp. OR mesenchymal stem cell/OR mesenchymal
stromal cells.mp. or mesenchymal stroma cell/OR bone marrow stromal
cells.mp.) AND (spinal cord injury.mp. or spinal cord injury/OR pain.mp. or
pain.mp. or neuropathic pain.mp. OR allodynia.mp. OR hyperalgesia.mp. OR
hypersensitivity.mp.). In addition, we ran a hand search in the reference lists
of all relevant articles and previous review articles to ﬁnd additional studies.
We also attempted to contact the authors of all the studies that met the
inclusion criteria and we requested unpublished data and abstracts.Ta
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In the present meta-analysis, the controlled studies assessing the
administration of BMMSCs to rat or mouse models of neuropathic painwere
included. Peripheral and central models of neuropathic pain induced by
contusion, compression, transection, and ligation were studied. Original
research studies about the inﬂuence of BMMSC transplantation, regardless
of donor species or tissue origin, were included. Outcomes measured were
the evaluation of allodynia [44] and hyperalgesia [45]. Control interventions
consisted of placebo (saline, culture medium, or similar vehicle) or no
treatment. Any manipulation of BMMSCs into neuron-like cells, coculture
concomitant injection with other cell types, or use of adjuvant products (eg,
matrices, scaffolding), and diabetic neuropathy lead to exclusion. In addi-
tion, review articles, commentaries, editorials, and letters were excluded.
Two authors (M.Y, H.A) independently appraised all potentially included
studies. Any disagreement was resolved using the viewpoint of a third
author (F.N). We included all the experimental studies regarding animals in
any age, gender, or strain exposed to neuropathic pain induced by contusion,
compression, transection, and ligation. Those that had poor quality were
excluded.
M. Hosseini et al. / Biol Blood Marrow Transplant 21 (2015) 1537e1544 1539Quality Assessment
Two reviewers (M.Y, H.A) independently evaluated each study and
allocated them a quality rating of “good,” “fair,” or “poor.” Quality assess-
ment was conducted to evaluate the impact of methodological quality on
the reported outcomes, accounting for study design and presence of bias,
including performance, recording, and reporting bias. In this regard, ade-
quacy of randomization and concealment of allocation, blinding of study
personnel and outcome assessors, and registered sample size estimations or
power calculations were assessed (inter-rater reliability was 91%). Dis-
agreements were discussed with a third reviewer (F.N).Data Synthesis
The following data were collected and recorded: recipient animal
(species, strain, sex, weight), type of neuropathy (contusion, compression,
transection, and ligation), type of graft (autologous, syngeneic, allogeneic, or
xenogeneic), intervention regimen (time from inducing the neuropathic
pain to cell transplantation, delivery route, number of injections, and total
number of transplanted cells), immunosuppressive usage, methodological
quality, observation (follow-up) time, and main ﬁndings.Statistical Analysis
Statistical analysis was performed using Stata software, version 12.0
(Stata Corp, College Station, TX). Effect sizes were computed and the stan-
dardized mean difference (SMD) with 95% conﬁdence interval (CI) was
entered in all analyses using Hedges’ g. By calculating the effect size, pooling
the ﬁndings and modifying the bias caused by small sample size were
possible [43,46]. The authors were contacted if mean values and standard
deviations (SD) were not reported. In case of no response, an estimation
method was used for the calculation of mean values and SD [47,48]. If the
information was reported as graphs, data were extracted from the graphs
using the method recommended by Sistrom and Mergo [48]. If the thera-
peutic effect of different numbers of cells in therapy was reported, the
highest number was included in the analysis. In addition, the mean and SD
of the latest time of follow-up period of included studies were used.Figure 1. Flow chartBased on the experimental diversity between the studies, random-
effects models or ﬁxed-effects models were used for data analysis.
Random-effects models were used in the presence of heterogeneity, and in
the absence of heterogeneity, ﬁxed-effects models were used. Statistical
heterogeneity was measured using the I2 and chi-square tests. In this regard,
P < .10 was the representative of signiﬁcant statistical heterogeneity [49].
Sensitivity and subgroup analyses were performed to investigate expected
or measured heterogeneity and applied based on a multivariate meta-
regression model. All possible causes of heterogeneity including the
animal gender (male/female), type of neuropathy (central or peripheral
nervous system), delivery route (spinal, intravenous, and dorsal root
ganglia), graft type (xenogeneic, allogeneic), time between injury and
intervention (equal and fewer than 4 days/more than 4 days), number of
transplanted cells (less than 3  106 cell dose/kg and more than or equal to
3 106 cell dose/kg), and follow-up period (fewer than 8 weeks and equal to
or more than 8 weeks) were included as covariates in the meta-regression
model. Publication bias was assessed using funnel plots and formal
Egger’s and Begg’s tests [50]. A 2-sided P value < .05 was considered sta-
tistically signiﬁcant.RESULTS
We found 2158 nonduplicate articles using the search
strategies described earlier. Of these, 136 potentially relevant
papers were screened. Finally, 13 full-text articles were
included for the meta-analysis and were studied in detail
[6,22-24,33-41] (Table 1). In addition, 1 eligible unpublished
set of data, which were obtained from an experiment in our
lab, were included in the analysis (unpublished data, F.
Nasirinezhad, July 2015). In this study Mean (standard de-
viation) of heat hyperalgesia in BMMSCs treated and control
groups were 20.2 (6.8) seconds and 9.7 (3.1) seconds,
receptively (10 rats per each groups). In addition, theseof the study.
M. Hosseini et al. / Biol Blood Marrow Transplant 21 (2015) 1537e15441540values for mechanical allodynia were 13.2 (2.27) grams and
7.1 (2.7) grams, respectively. The ﬂow of information from
identiﬁcation to inclusion of studies is summarized in
Figure 1. These citations contained a total of 373 rats/mice
including 206 BMMSC-treated animals and 167 controls. Of
the 14 articles, 4 reported only the impact of BMMSCs
transplantation on hyperalgesia [22,35,39,40] and 4 assessed
its effect on allodynia [23,33,34,41]. Six articles evaluated the
effect on both [6,24,36-38].Heterogeneity and Publication Bias
According to the result of subgroup analysis of the ther-
apeutic effect of BMMSCs, a signiﬁcant statistical heteroge-
neity was found on neuropathic pain, except regarding
delivery route (I2 ¼ .0%; P ¼ .74). Therefore, in this case a
ﬁxed-effects model was used, whereas other analyses were
performed using a random-effects model. No publication
bias was observed among the included studies (Tables 2 and
3). In addition, we were not able to calculate the pooled-
effect size in xenogeneic graft of BMMSCs because eligible
related studies were few (2 studies).Table 2
Subgroup Analyses of the Effect of BMMSC on Mechanical Allodynia
Characteristic P for Bias* Mod
Gender
Male .34 REM
Female .19 REM
Overall signiﬁcance test among subgroups
Type of neuropathy
Central .45 REM
Peripheral .73 REM
Overall signiﬁcance test among subgroups
Randomization
No .33 REM
Yes .76 REM
Overall signiﬁcance test among subgroups
Blinding the outcome assessment
No .49 REM
Yes .64 REM
Overall signiﬁcance test among subgroups
Delivery route
Spinal .14 REM
Intravenous .23 REM
DRG .65 FEM
Overall signiﬁcance test among subgroups
Graft type
Xenogeneic .32 REM
Allogeneic .61 REM
Overall signiﬁcance test among subgroups
Use of immunosuppressive agents
No NA NA
Yes .73 REM
Overall signiﬁcance test among subgroups
Time between injury and interventionx
Less than 4 d .28 REM
More than 4 d .13 REM
Overall signiﬁcance test among subgroups
Number of transplanted cells
Less than 3  106 cell dose/kg .33 REM
More than or equal to 3  106 cell dose/kg .52 REM
Overall signiﬁcance test among subgroups
Follow-up period
Less than 8 wk .19 REM
More than or equal to 8 wk .73 REM
Overall signiﬁcance test among subgroups
REM indicates random-effect model; FEM, ﬁxed-effect model; DRG, dorsal root ga
* Publication bias based on Begg’s and Egger’s test.
y Heterogeneity among studies.
z Standardized mean difference.
x Categorization was done based on median of time between injury and interveMeta-Analysis
The main outcome measure was the assessment of
hyperalgesia and allodynia. According to our analysis, using
the random-effects model, BMMSC transplantation leads to a
statistically signiﬁcant improvement on allodynia (SMD ¼
2.06; 95% CI, 1.09 to 3.03; I2 ¼ 99.7%; P < .001) but does not
have a signiﬁcant effect on hyperalgesia (SMD ¼ .3; 95%
CI, 1.09 to 1.68; I2 ¼ 100%; P < .001) (Figures 2 and 3).Subgroup Analyses
Subgroup analyses were performed based on animal
gender, type of neuropathy, randomization, blinding of
observer, stem cell delivery route, xenogeneic or allogeneic
transplantation, use of immunosuppressive agents, time
between injury and intervention, number of transplanted
cells, and follow-up periods.
Allodynia
Table 2 presents the subgroup analysis of allodynia.
Multivariate meta-regression showed that the type of neu-
ropathy (P ¼ .036), time between injury and interventionel P (I2)y Effect Sizez (95% CI) P
<.001 (99.3%) 2.45 (1.69-3.2) <.001
<.001 (99.6%) 1.16 (e.58-2.90) .19
.49
<.001 (96.1%) 1.0 (.28-1.71) .006
<.001 (99.7%) 2.06 (1.09-3.03) <.001
.036
<.001 (99.8%) 2.05 (.74-3.35) .002
<.001 (89.7%) 2.36 (1.44-3.17) <.001
.17
<.001 (99.8%) 1.82 (e.10-3.73) .06
<.001 (99.4%) 2.26 (1.33-3.19) <.001
.37
<.001 (99.0%) 1.32 (.35-2.28) .007
<.001 (99.4%) 3.53 (2.59-4.47) <.001
.74 (.0%) 3.02 (2.92-3.12) <.001
.255
<.001 (99.9%) 2.33 (e.98-5.63) .17
<.001 (99.7%) 1.99 (.96-3.02) <.001
.99
NA NA NA
<.001 (99.7%) 2.23 (1.22-3.25) <.001
NA
<.001 (98.9%) 3.1 (2.53-3.68) <.001
<.001 (95.6%) 1.08 (.44-1.72) .001
.02
<.001 (86.9%) .81 (.35-1.26) <.001
<.001 (98.9%) 2.98 (2.43-3.54) <.001
.023
<.001 (99.7%) 1.6 (.14-3.06) <.001
<.001 (99.5%) 2.54 (1.41-3.66) <.001
.72
nglia; NA, not applicable.
ntion in included studies.
Table 3
Subgroup Analyses of the Effect BMMSC on Heat Hyperalgesia
Characteristic P for Bias* Model P (I2)y Effect Sizez (95% CI) P
Gender
Male .37 REM <.001 (99.8%) 1.24 (e.74-3.22) .22
Female .78 REM <.001 (99.9%) .64 (e2.87-1.60) .58
Overall signiﬁcance test among subgroups .90
Randomization
No .29 REM <.001 (10.0%) e.005 (e2.12-1.10) .99
Yes .70 REM <.001 (97.9%) .78 (e1.27-2.82) .45
Overall signiﬁcance test among subgroups .86
Blinding the outcome assessment
No .53 REM <.001 (100.0%) e.61 (e3.62-2.41) .69
Yes .80 REM <.001 (99.9%) 1.22 (e1.05-3.49) .29
Overall signiﬁcance test among subgroups .37
Type of neuropathy
Central .44 REM <.001 (99.8%) e.72 (e2.78-1.35) .50
Peripheral .49 REM <.001 (99.7%) 2.65 (.68-4.61) .008
Overall signiﬁcance test among subgroups .722
Delivery route
Spinal .20 REM <.001 (99.9%) e.4 (e2.23-1.42) .66
Intravenous .49 REM <.001 (99.8%) 1.96 (.04-3.95) .054
Overall signiﬁcance test among subgroups .765
Graft typex
Xenogeneic NA NA NA NA NA
Allogeneic .79 REM <.001 (99.9%) e.22 (e1.63-1.20) .77
Overall signiﬁcance test among subgroups NA
Use of immunosuppressive agents
No .69 REM .01 (83.0%) e.78 (e2.1-.56) .25
Yes .88 REM <.001 (99.9%) .57 (e.98-2.10) .47
Overall signiﬁcance test among subgroups .79
Time between injury and interventiond
Less than 4 d .11 REM <.001 (99.9%) 2.65 (.68-4.61) .008
More than 4 d .13 REM <.001 (99.8%) e.72 (e2.78-1.35) .50
Overall signiﬁcance test among subgroups .022
Number of transplanted cells
Less than 3  106 cell dose/kg .12 REM <.001 (98.2%) e.31 (e1.54-.91) .62
More than or equal to 3 106 cell dose/kg .80 REM <.001 (100.0%) .69 (e1.28-2.66) .49
Overall signiﬁcance test among subgroups .99
Follow-up period
Less than 8 wk .11 REM <.001 (98.2%) .16 (e4.56-4.88) .30
More than or equal to 8 wk .59 REM <.001 (99.8%) .50 (e.44-1.44) .95
Overall signiﬁcance test among subgroups .99
* Publication bias based on Begg’s and Egger’s test.
y Heterogeneity among studies.
z Standardized mean difference.
x Categorization was done based on median of time between injury and intervention in included studies.
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inﬂuence the improvement of allodynia after BMMSC
transplantation. The effect sizes of BMMSC transplantation
on central and peripheral neuropathy were 1.0 (95% CI, .28 to
1.71) and 1.16 (95% CI, 1.09 to 3.03), respectively. The analysis
showed that the effect of BMMSC transplantation on allo-
dynia was greater in the peripheral model (P ¼ .036). Time
between injury and intervention were categorized based on
4 days. Subgroup analysis showed that stem cell therapy
during ﬁrst 4 days (effect size ¼ 3.1; 95% CI, 2.53 to 3.68) is
more effective than after 4 days (effect size¼ 1.08; 95% CI, .44
to 1.72) (P ¼ .02). In addition, multivariate meta-regression
depicts stem cell therapy with a dose of more than or equal
to 3106 cell dose/kg (effect size¼ 2.98; 95% CI, 2.43 to 3.54)
is more effective than cell therapy with dose of less than 3 
106 cell dose/kg (effect size ¼ 2.98; 95% CI, 2.43 to 3.54) (P ¼
.023).
Hyperalgesia
Multivariate meta-regression showed that cell therapy
correlated with more improvement in hyperalgesia if it
occurred during ﬁrst 4 days after injury (P ¼ .02). Stem cell
therapy during ﬁrst 4 days (effect size ¼ 2.65; 95% CI, .68 to
4.61) is more effective than after 4 days (effect size ¼ .72;95% CI, 2.78 to 1.35) (P ¼ .02). Table 3 presents the subgroup
analysis of the effect of stem cell therapy on hyperalgesia.
DISCUSSION
Meta-analyses of animal studies provide practical evi-
dence for researchers regarding advantages and side effects
of an intervention to help them decide to proceed with
clinical trials or not. Based on our knowledge, the present
study is the ﬁrst quantitative meta-analytic approach to re-
view all of the available evidence regarding the efﬁcacy of
BMMSCs in improving neuropathic pain. The analyses
showed that BMMSC transplantation leads to a statistically
signiﬁcant improvement on allodynia but does not have a
signiﬁcant effect on hyperalgesia. We found signiﬁcant di-
versity between the studies. Therefore, subgroup analysis
was performed to assess possible sources of the heteroge-
neity. Based on this analysis, type of neuropathy (central or
peripheral), time from injury to intervention, and the num-
ber of transplanted cells were the most important causes of
the heterogeneity. In addition, among 14 included articles, 1
paper assessed the stem cell therapy in a mouse model [37].
Subgroup analysis was not performed based on animal spe-
cies because of the small number of included studies. How-
ever, in the mentioned study, there was the strongest effect
Figure 2. The effect of BMMSC transplantation on mechanical allodynia.
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a species difference between rat and mouse. Further studies
are required to conﬁrm this hypothesis.
Currently, there are 2 experimental animal models of
neuropathic pain, including peripheral and central
models [51-53]. Subgroup analysis showed that BMMSC
transplantation leads to more improvement in allodynia
induced in the peripheral model compared with in theFigure 3. The effect of BMMSC transpcentral model. This ﬁnding is partly due to the different
mechanism of neuropathic pain in the central and peripheral
models. In peripheral models, altered ion channel expression
triggers enhanced membrane resonance, rhythmogenesis,
and ectopic spiking with increased cellular excitability,
which are the most important mechanisms of inducing the
neuropathic pain. Sprouting of myelinated nerve ﬁbers into
lamina II, increased glutamate release, evoking fastlantation on heat hyperalgesia.
M. Hosseini et al. / Biol Blood Marrow Transplant 21 (2015) 1537e1544 1543excitatory synaptic potentials, expression of brain-derived
neurotrophic factor and substance P, neuroplasticity
changes in central pain descending regulatory systems, and
astrocytes and glial cell activation are the most important
mechanisms in central models. BMMSC transplantation
provides a protective effect for the host cells. Efﬁcacy of this
supportive role may be greater in reversing the pathophys-
iological changes in the peripheral model [54-56].
The development of secondary spinal cord damage sets in
the early minutes after injury and continues for weeks or
months. The mechanisms involved in secondary spinal cord
damage consist of apoptosis, astroglial scar launch, central
cavitation, central chromatolysis, compression and vertebral
column instability, deﬁcient expression of myelin associated
genes after spinal cord injury, demyelination of residual
axons, derangements in ionic homeostasis, glutamatergic
excitotoxicity, immune cells invasion and release of cyto-
kines, inﬂammation, and ischemia/reperfusion-induced
endothelial damage, etc. [57]. BMMSCs have immunomod-
ulatory properties [18,58-60] and, when administered at the
right time, may help in minimizing neural inﬂammation and
immune-mediated injuries. Early cell therapy might
decrease proliferation or hypertrophy of glial cells (gliosis)
and enhance recovery by bioactive molecules, modulation of
cytokine production, and growth factors. Also, the angio-
genic effect of these cells may help the revascularization of
spinal cord [61,62]. In this regard, our ﬁndings also showed
that onset of stem cell therapy during the ﬁrst days after
injury (fewer than 4 days) causes more improvement in
allodynia and hyperalgesia. Accordingly, it seems rational to
suggest that the optimal time point for transplantation is
fewer than 4 days after the lesion. A similar result was re-
ported in another systematic review, which stated that the
optimal time point for transplantation of stem cells in spinal
cord injury is 3 days after the lesion for intralesional site and
5 to 7 days for intrathecal injection [63].
Median stem cell transplantation dose in the eligible
studies was 2.25  106 cells/kg. We categorized the number
of transplanted cells into 2 groups (based on 3  106 cell
dose/kg). This cut point was selected because it is near the
typical number of transplanted cells currently administrated
in clinical trials (1 to 3  106 cell dose/kg) [29,64,65]. Our
result demonstrated that stem cell therapy in doses of 3 
106 or higher is associated with greater improvement in
allodynia. The correlation between the number of trans-
planted cells and recovery after spinal cord injury was
reported in 2 studies. The studies demonstrated a dose-
dependent inﬂuence of BMMSCs on recovery after spinal
cord injury [66,67]. BMMSCs display immunosuppressive
properties in a dose-dependent manner [58,68]. Subse-
quently, the development of secondary damage was reduced
and survival rate of transplanted cells increased.
Strengths and Limitations
In the present study, 3 points have improved the quality
of our meta-analysis. First, we assessed both central and
peripheral models of neuropathic pain. Second, we calcu-
lated SMDs as the effect size estimate using Hedges’ g to
compare across articles and to correct for bias caused by
small sample size. Third, subgroup analysis was performed
stratiﬁed by animal gender, type of neuropathy, delivery
route, graft type, time between injury and intervention,
number of transplanted cells, and follow-up period, because
heterogeneity is expected in most meta-analyses. In addi-
tion, we conducted an extensive search and used acomprehensive analytical approach that allowed the inclu-
sion of studies presenting not only means and SD, but also
other values, such as medians, thus improving the exhaus-
tiveness of the results.
Our review and meta-analysis have a number of limita-
tions. First, some of the original studies did not describe the
blinding status of the observer. Moreover, residual con-
founding (confounding from unknown variables), as inmeta-
analyses, may introduce considerable bias, and the direction
of this bias is unpredictable. Second, the possible source of
heterogeneity between the studies was not clear. Therefore,
it was decided to use a random-effects model, which gave
more conservative results. In addition, we ran a meta-
regression and stratiﬁed meta-analysis by partitioning of
heterogeneity.
CONCLUSION
The present systematic review with meta-analysis seem
to suggest that BMMSC transplantation improved allodynia
but had no signiﬁcant effect on hyperalgesia. The effective-
ness of BMMSCs on neuropathic pain is higher if they are
transplanted for peripheral pain, in fewer than 4 days, and in
a dose of equal to or more than 3  106 cells per kg.
ACKNOWLEDGMENTS
Financial disclosure statement: This research has been
supported by a Tehran University of Medical Sciences and
Health Services grant (grant number: 93-03-27-27180).
Conﬂict of interest statement: There are no conﬂicts of in-
terest to report.
REFERENCES
1. Jensen TS, Baron R, Haanpää M, et al. A new deﬁnition of neuropathic
pain. Pain. 2011;152:2204-2205.
2. Nurcan ÃÃ, Sommer C. Neuropathic pain assessment: an overview of
existing guidelines and discussion points for the future. Eur Neurol Rev.
2011;6:128-131.
3. Van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general
population: a systematic review of epidemiological studies. Pain. 2014;
155:654-662.
4. Bennett MI, Smith BH, Torrance N, Lee AJ. Can pain can be more or less
neuropathic? Comparison of symptom assessment tools with ratings of
certainty by clinicians. Pain. 2006;122:289-294.
5. Dieleman JP, Kerklaan J, Huygen FJ, et al. Incidence rates and treatment
of neuropathic pain conditions in the general population. Pain. 2008;
137:681-688.
6. Klass M, Gavrikov V, Drury D, et al. Intravenous mononuclear marrow
cells reverse neuropathic pain from experimental mononeuropathy.
Anesth Analg. 2007;104:944-948.
7. Klein S, Svendsen CN. Stem cells in the injured spinal cord: reducing
the pain and increasing the gain. Nat Neurosci. 2005;8:259-260.
8. Jergova S, Hentall ID, Gajavelli S, et al. Intraspinal transplantation of
GABAergic neural progenitors attenuates neuropathic pain in rats: a
pharmacologic and neurophysiological evaluation. Exp Neurol. 2012;
234:39-49.
9. Borsani E, Franchi S, Rossi A, et al. Stem cell transplantation in
neuropathic pain. Ital J Anot Emberyol. 2011;116:31.
10. Lin CR, Wu PC, Shih HC, et al. Intrathecal spinal progenitor cell trans-
plantation for the treatment of neuropathic pain. Cell Transplant. 2002;
11:17-24.
11. Eaton M, Plunkett J, Martinez M, et al. Transplants of neuronal cells
bioengineered to synthesize GABA alleviate chronic neuropathic pain.
Cell Transplant. 1999;8:87.
12. Liang Y, Jiang W, Zhang Z, et al. Behavioral and morphological evidence
for the involvement of glial cells in the antinociceptive effect of naja-
nalgesin in a rat neuropathic pain model. Biol Pharm Bull. 2012;35:
850-854.
13. Pirhajati Mahabadi V, Tiraih T, Khalatbary A. Central neuropathic pain
after graft of bone marrow stromal cells in the spinal cord contusion of
rat. J Iran Anatomic Sci. 2007;5:93-105.
14. Klopp AH, Gupta A, Spaeth E, et al. Concise review: dissecting a
discrepancy in the literature: do mesenchymal stem cells support or
suppress tumor growth? Stem Cells. 2011;29:11-19.
15. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult
human mesenchymal stem cells. Science. 1999;284:143-147.
M. Hosseini et al. / Biol Blood Marrow Transplant 21 (2015) 1537e1544154416. Anjos-Afonso F, Siapati EK, Bonnet D. In vivo contribution of murine
mesenchymal stem cells into multiple cell-types under minimal
damage conditions. J Cell Sci. 2004;117:5655-5664.
17. Wakitani S, Imoto K, Yamamoto T, et al. Human autologous culture
expanded bone marrow mesenchymal cell transplantation for repair of
cartilage defects in osteoarthritic knees. Osteoarthritis Cartilage. 2002;
10:199-206.
18. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal
stromal cells. Blood. 2007;110:3499-3506.
19. Puissant B, Barreau C, Bourin P, et al. Immunomodulatory effect of
human adipose tissueederived adult stem cells: comparison with bone
marrow mesenchymal stem cells. Br J Haematol. 2005;129:118-129.
20. Bae JS, Han HS, Youn DH, et al. Bone marrowederived mesenchymal
stem cells promote neuronal networks with functional synaptic
transmission after transplantation into mice with neurodegeneration.
Stem Cells. 2007;25:1307-1316.
21. Cho KJ, Trzaska KA, Greco SJ, et al. Neurons derived from human
mesenchymal stem cells show synaptic transmission and can be
induced to produce the neurotransmitter substance P by interleukin-
1a. Stem Cells. 2005;23:383-391.
22. Amemori T, Jendelová P, Ruzicková K, et al. Co-transplantation of ol-
factory ensheathing glia and mesenchymal stromal cells does not have
synergistic effects after spinal cord injury in the rat. Cytotherapy. 2010;
12:212-225.
23. Guo W, Wang H, Zou S, et al. Bone marrow stromal cells produce long-
term pain relief in rat models of persistent pain. Stem Cells. 2011;29:
1294-1303.
24. Kumagai G, Tsoulfas P, Toh S, et al. Genetically modiﬁed mesenchymal
stem cells (MSCs) promote axonal regeneration and prevent hyper-
sensitivity after spinal cord injury. Exp Neurol. 2013;248:369-380.
25. Kishk NA, Gabr H, Hamdy S, et al. Case control series of intrathecal
autologous bone marrow mesenchymal stem cell therapy for chronic
spinal cord injury. Neurorehabil Neural Repair. 2010;24:702-708.
26. Ichim TE, Solano F, Lara F, et al. Feasibility of combination allogeneic
stem cell therapy for spinal cord injury: a case report. Int Arch Med.
2010;3:30.
27. Syková E, Homola A, Mazanec R, et al. Autologous bone marrow
transplantation in patients with subacute and chronic spinal cord
injury. Cell Transplant. 2006;15:675-687.
28. Geffner L, Santacruz P, Izurieta M, et al. Administration of autologous
bone marrow stem cells into spinal cord injury patients via multiple
routes is safe and improves their quality of life: comprehensive case
studies. Cell Transplant. 2008;17:1277-1293.
29. Kumar AA, Kumar SR, Narayanan R, et al. Autologous bone marrow
derived mononuclear cell therapy for spinal cord injury: a phase I/II
clinical safety and primary efﬁcacy data. Exp Clin Transplant. 2009;7:
241-248.
30. Pal R, Venkataramana NK, Bansal A, et al. Ex vivo expanded autologous
bone marrow-derived mesenchymal stromal cells in human spinal
cord injury/paraplegia: a pilot clinical study. Cytotherapy. 2009;11:
897-911.
31. Moviglia G, Varela G, Gaeta C, et al. Autoreactive T cells induce in vitro
BM mesenchymal stem cell transdifferentiation to neural stem cells.
Cytotherapy. 2006;8:196-201.
32. Fawcett J, Curt A, Steeves J, et al. Guidelines for the conduct of clinical
trials for spinal cord injury as developed by the ICCP panel: sponta-
neous recovery after spinal cord injury and statistical power needed for
therapeutic clinical trials. Spinal Cord. 2006;45:190-205.
33. Lee KH, Suh-Kim H, Choi JS, et al. Human mesenchymal stem cell
transplantation promotes functional recovery following acute spinal
cord injury in rats. Acta Neurobiol Exp (Wars). 2007;67:13-22.
34. Musolino PL, Coronel MF, Hökfelt T, Villar MJ. Bone marrow stromal
cells induce changes in pain behavior after sciatic nerve constriction.
Neurosci Lett. 2007;418:97-101.
35. Neuhuber B, Timothy Himes B, Shumsky JS, et al. Axon growth and
recovery of function supported by human bone marrow stromal cells
in the injured spinal cord exhibit donor variations. Brain Res. 2005;
1035:73-85.
36. Schäfer S, Berger JV, Deumens R, et al. Inﬂuence of intrathecal delivery
of bone marrow-derived mesenchymal stem cells on spinal inﬂam-
mation and pain hypersensitivity in a rat model of peripheral nerve
injury. J Neuroinﬂammation. 2014;11:157.
37. Siniscalco D, Giordano C, Galderisi U, et al. Long-lasting effects of hu-
man mesenchymal stem cell systemic administration on pain-like
behaviors, cellular, and biomolecular modiﬁcations in neuropathic
mice. Front Integr Neurosci. 2011;5:79.
38. Torres-Espín A, Redondo-Castro E, Hernández J, Navarro X. Bone
marrow mesenchymal stromal cells and olfactory ensheathing cells
transplantation after spinal cord injuryea morphological and func-
tional comparison in rats. Eur J Neurosci. 2014;39:1704-1717.
39. Urdzíková L, Jendelová P, Glogarová K, et al. Transplantation of bone
marrow stem cells as well as mobilization by granulocyte-colony
stimulating factor promotes recovery after spinal cord injury in rats.
J Neurotrauma. 2006;23:1379-1391.40. Vaquero J, Zurita M, Oya S, Santos M. Cell therapy using bone marrow
stromal cells in chronic paraplegic rats: systemic or local administra-
tion? Neurosci Lett. 2006;398:129-134.
41. Zhang EJ, Song CH, Ko YK, Lee WH. Intrathecal administration of
mesenchymal stem cells reduces the reactive oxygen species and pain
behavior in neuropathic rats. Korean J Pain. 2014;27:239-245.
42. Vesterinen HM, Sena ES, Egan KJ, et al. Meta-analysis of data from
animal studies: a practical guide. J Neurosci Methods. 2014;221:92-102.
43. Sena ES, Currie GL, McCann SK, et al. Systematic reviews and meta-
analysis of preclinical studies: why perform them and how to
appraise them critically. J Cereb Blood Flow Metab. 2014;34:737-742.
44. Chaplan S, Bach F, Pogrel J, et al. Quantitative assessment of tactile
allodynia in the rat paw. J Neurosci Methods. 1994;53:55-63.
45. Montagne-Clavel J, Oliveras J-L. The “plantar test” apparatus (Ugo
Basile Biological Apparatus), a controlled infrared noxious radiant heat
stimulus for precise withdrawal latency measurement in the rat, as a
tool for humans? Somatosens Mot Res. 1996;13:215-223.
46. Higgins JP, Green S. Cochrane handbook for systematic reviews of in-
terventions. Chichester: Wiley Online Library; 2008.
47. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from
the median, range, and the size of a sample. BMC Med Res Methodol.
2005;5:13.
48. Sistrom CL, Mergo PJ. A simple method for obtaining original data from
published graphs and plots. Am J Roentgenol. 2000;174:1241-1244.
49. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsis-
tency in meta-analyses. BMJ (Clinical Research ed). 2003;327:557-560.
50. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ. 1997;315:629-634.
51. Ildikó R, Zimmer A. Animal models of nociception. In: Hrabé de
AngelisMartin, ChambonPierre, Brown Steve, editors. Standards ofMouse
Model Phenotyping., 53. Chichester: Wiley-Blackwell; 2009. p. 221-235.
52. Le Bars D, Gozariu M, Cadden SW. Animal models of nociception.
Pharmacol Rev. 2001;53:597-652.
53. Mogil JS. Animal models of pain: progress and challenges. Nat Rev
Neurosci. 2009;10:283-294.
54. Burnett MG, Zager EL. Pathophysiology of peripheral nerve injury: a
brief review. Neurosurg Focus. 2004;16:1-7.
55. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells
and glia. Nat Neurosci. 2007;10:1361-1368.
56. Klusáková I, Dubový P. Experimental models of peripheral neuropathic
pain based on traumatic nerve injuriesean anatomical perspective. Ann
Anat. 2009;191:248-259.
57. Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord
injury: a nugget of this multiply cascade. Acta Neurobiol Exp (Wars).
2011;71:281-299.
58. Montespan F, Deschaseaux F, Sensébé L, et al. Osteodifferentiated
mesenchymal stem cells from bone marrow and adipose tissue express
HLA-G and display immunomodulatory properties in HLA-mismatched
settings: implications in bone repair therapy. J Immunol Res. 2014;
2014:1-10.
59. Hou R, Liu R, Niu X, et al. Biological characteristics and gene expression
pattern of bone marrow mesenchymal stem cells in patients with
psoriasis. Exp Dermatol. 2014;23:521-523.
60. Menendez P, Rodriguez R, Delgado M, Rosu-Myles M. Human bone
marrow mesenchymal stem cells lose immunosuppressive and anti-
inﬂammatory properties upon oncogenic transformation. Exp Hema-
tol. 2014;42:S49.
61. Zeng X, Zeng YS, Ma YH, et al. Bone marrow mesenchymal stem cells in
a three-dimensional gelatin sponge scaffold attenuate inﬂammation,
promote angiogenesis, and reduce cavity formation in experimental
spinal cord injury. Cell Transplant. 2011;20:11-12.
62. Parr AM, Tator CH, Keating A. Bone marrow-derived mesenchymal
stromal cells for the repair of central nervous system injury. Bone
Marrow Transplant. 2007;40:609-619.
63. Oudega M, Ritfeld G. Bone marrow-derived mesenchymal stem cell
transplant survival in the injured rodent spinal cord. J Bone Marrow Res.
2014;2:2-9.
64. Deda H, Inci M, Kürekçi A, et al. Treatment of chronic spinal cord
injured patients with autologous bone marrow-derived hematopoietic
stem cell transplantation: 1-year follow-up. Cytotherapy. 2008;10:
565-574.
65. Yoon SH, Shim YS, Park YH, et al. Complete spinal cord injury treat-
ment using autologous bone marrow cell transplantation and bone
marrow stimulation with granulocyte macrophage-colony stimulating
factor: phase I/II clinical trial. Stem Cells. 2007;25:2066-2073.
66. Pal R, Gopinath C, Rao NM, et al. Functional recovery after trans-
plantation of bone marrow-derived human mesenchymal stromal cells
in a rat model of spinal cord injury. Cytotherapy. 2010;12:792-806.
67. Li H, Wen Y, Luo Y, et al. Transplantation of bone marrow mesen-
chymal stem cells into spinal cord injury: a comparison of delivery
different times. Chin J Repar Reconstr Surg. 2010;24:180-184.
68. Krampera M, Cosmi L, Angeli R, et al. Role for interferon-g in the
immunomodulatory activity of human bone marrow mesenchymal
stem cells. Stem Cells. 2006;24:386-398.
